Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitomycin C vs interferon alfa-2b vs bevacizumab after primary pterygium surgery
IRCT20220215054028N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of mitomycin c, interferon alfa-2b and bevacizumab in pterygium (3 arms), sponsored by Mashhad University of Medical Sciences. Started May 2022; status: completed.
02
Drugs
mitomycin cinterferon alfa-2bbevacizumab
03
Conditions
pterygium
Beyond the preview
Go deeper on IRCT20220215054028N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220215054028N1.